论文部分内容阅读
异名 Alradase 化学名 N-{[6-甲氧基-5-(三氟甲基)-1-萘基]-硫代甲基}-N-甲基甘氨酸药效分类醛糖还原酶抑制剂开发单位 (爱尔兰)Wyeth Laboratories Ltd 上市厂商 (爱尔兰)Wyeth Laboratories Ltd 1989年上市药理和药动学口服Tolrestat后2小时达最高血浓度,一次或多次用药后,半减期约10～12小时,在25～800mg剂量范围内,生物利用度与剂量成线性关系。Tolrestat与血浆蛋白广泛结合,游离的Tolrestat在0.5%以下,其消除形式主要以原形随尿液排出,同时含有少量共轭的和硫代的Tolrestat代谢物。在10～800mg剂量范围内,吸收
Synonyms Alradase Chemical name N - {[6-methoxy-5- (trifluoromethyl) -1-naphthyl] -thiomethyl} -N-methylglycine Pharmacodynamic classification Aldose reductase inhibitor Development Unit (Ireland) Wyeth Laboratories Ltd Listed Company (Ireland) Wyeth Laboratories Ltd Listed on Pharmacology and Pharmacology in 1989 Up to 2 hours after Tolrestat oral administration, the maximum blood concentration is achieved. After one or more doses, the half-time period is about 10 to 12 hours, In the 25 ~ 800mg dose range, bioavailability and dose into a linear relationship. Tolrestat binds extensively to plasma proteins with less than 0.5% free Tolrestat, and its elimination forms are mainly excreted in urine as a prototype with a small amount of conjugated and thio-Tolrestat metabolites. In the 10 ~ 800mg dose range, absorption